Provided by Tiger Fintech (Singapore) Pte. Ltd.

SpringWorks Therapeutics, Inc.

44.72
-0.2100-0.47%
Post-market: 44.750.0300+0.07%19:56 EDT
Volume:7.81M
Turnover:347.89M
Market Cap:3.35B
PE:-12.84
High:45.01
Open:44.85
Low:44.19
Close:44.93
Loading ...

Merck KGaA CEO Says We Refer to Our Previous Statement on SpringWorks, When Asked About Any Progress of Talks

THOMSON REUTERS
·
06 Mar

Investors push SpringWorks Therapeutics (NASDAQ:SWTX) 4.9% lower this week, company's increasing losses might be to blame

Simply Wall St.
·
06 Mar

Is SpringWorks Therapeutics, Inc. (SWTX) The Best Immunology Stock To Buy Now?

Insider Monkey
·
02 Mar

J.P. Morgan Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)

TIPRANKS
·
25 Feb

SpringWorks Therapeutics Price Target Maintained With a $74.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Feb

BUZZ-SpringWorks Therapeutics rises as canceled earnings call raises buyout hopes

Reuters
·
20 Feb

Springworks Therapeutics Q4 Net Loss Narrows

MT Newswires Live
·
20 Feb

Stock Track | SpringWorks Therapeutics Soars 14.88% in Pre-market on Strong Q4 Revenue, FDA Approval for New Drug

Stock Track
·
20 Feb

Earnings Flash (SWTX) Springworks Therapeutics Posts Q4 Net Loss $-1.04 a Share, vs. FactSet Est of $-0.71 Loss

MT Newswires Live
·
20 Feb

SpringWorks Therapeutics FY 2024 GAAP EPS $(3.48) Misses $(3.06) Estimate, Sales $191.59M Beat $190.92M Estimate

Benzinga
·
20 Feb

SpringWorks Therapeutics FY Basic EPS USD -3.48

THOMSON REUTERS
·
20 Feb

SpringWorks Therapeutics Shares up 6% Premarket Ahead of Q4 Results

THOMSON REUTERS
·
20 Feb

SpringWorks, Jennifer Fisher team to increase understanding of desmoid tumors

TIPRANKS
·
19 Feb

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Zacks
·
14 Feb

SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25

TipRanks
·
13 Feb

SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
13 Feb

SpringWorks Therapeutics CEO sells $2.56M in common stock

TIPRANKS
·
13 Feb

Wedbush ups SpringWorks target to $81, expects Merck KGaA ‘official’ offer soon

TIPRANKS
·
13 Feb

SpringWorks sets wholesale acquisition cost for Gomekli at $206.25 per mg

TIPRANKS
·
13 Feb

SpringWorks Therapeutics Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
12 Feb